ArticleAnnals of neurosciences2026
Potential Effect of Belladonna in the Management of Convulsions in Zebrafish (
Article in Annals of neurosciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Convulsions (seizures) are common neurological conditions characterised by abnormal electrical activity in the brain. Various modern treatments are available for managing convulsions; however, due to the side effects of available treatments, alternative medicine is gaining attention. One of the most popular homoeopathic remedies is Belladonna, used for treating neurological symptoms such as seizures, but scientific evidence is not available. Purpose: The present study was designed to evaluate its anticonvulsive effect in the zebrafish animal model. Methodology: The effect of homoeopathic Belladonna on pentylenetetrazole (PTZ)-induced seizures in zebrafish (Danio rerio) was assessed in this study. The safe dose was identified through acute toxicity studies, which revealed that 0.25% and 0.5% were non-toxic to zebrafish larvae and adults, respectively. In seizure studies, zebrafish larvae and adults were pre-treated with Belladonna mother tincture (Bell-MT), Bell-6C and Bell-30C potencies, followed by PTZ exposure to induce epileptic responses. An in silico molecular docking study was performed with the help of the Glide tool of Schrödinger Suite 2022-4. Results: The total phenolic content (TPC) in Belladonna-MT was 292.61 µg of gallic acid/100% MT. In zebrafish larvae, Bell-6C and Bell-30C significantly increased the latency to reach seizure score 2 and score 3, compared to the PTZ group. In adult zebrafish, Bell-6C and Bell-30C pre-treatment resulted in significant delays in reaching seizure scores 1-5. Additionally, the number of rotations and total distance travelled were also improved after the Belladonna pre-treatment in larvae and adult zebrafish and suggest a marked protective effect against pentylenetetrazole (PTZ)-induced seizures in zebrafish. The possible mechanisms involved in the anti-convulsant activity of Belladonna were elucidated using molecular docking studies. Conclusion: Collectively, these findings support the potential of Belladonna as an anticonvulsant and could be a potential candidate for the management of epilepsy. However, further exploration for epilepsy management through the underlying mechanisms of action is needed in the future.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.